Applied Biopharm Consulting Ltd has relocated to a new business premises at the West Cork Business and Technology Park in Clonakilty, marking a pivotal moment in its expansion journey. The move demonstrates the company’s ambition to support rising international demand for specialist biologics and gene therapy consultancy.
Founded by Dr Anthony Newcombe—whose leadership background includes roles at GSK and Pfizer—the firm delivers expert guidance in areas such as GMP audits, MSAT, regulatory strategy for CMC, technical transfer, and QA. The consultancy is a trusted partner for biopharma firms advancing cutting-edge therapies, particularly in biologics and gene-modified treatments.
Over the past two years, Applied Biopharm has rapidly expanded its client base, forging partnerships with leading firms across the EU, US, and Asia-Pacific. The company’s ability to provide tailored, science-driven support has been a key driver of its growing reputation as a trusted advisor in the life sciences sector.
“This step reflects our continued growth and commitment to working with biotech innovators worldwide,” said Dr Newcombe. “Having a presence at the West Cork Business and Technology Park also puts us in a strong position to scale our activities in consulting, gene therapy, and bioprocess development. We’re excited to expand our footprint while staying close to the scientific and entrepreneurial ecosystem in Cork.”
As Applied Biopharm enters this new chapter, the company plans to deepen its investment in innovation, talent development, and strategic collaborations. Its new base in Clonakilty not only enhances operational capabilities but also reinforces the firm’s long-term vision of becoming a leading consulting partner in the global biotechnology industry.
About Applied Biopharm Consulting
Applied Biopharm Consulting Ltd delivers expert support to biopharma companies worldwide, specializing in auditing, biologics development, GMP compliance, technology transfer, regulatory CMC and quality assurance. With expertise spanning gene therapies, monoclonal antibodies, recombinant proteins and vaccines.